Cell2B appoints international advisory board

29 April 2014 — FacebookLinkedInEmail

Cell2B is honored to make public our long term commitment with our Advisory Board. Charles Cooney (PhD), Duke Collier (JD), and Frederic Chereau (MBA) have been very active since Cell2B’s incorporation. They bring outstanding experience in industry from start-up to corporate level and from rare diseases to cell therapies.


cooney300x300Charles L. Cooney is the Robert T. Haslam (1911) Professor of Chemical and Biochemical Engineering at MIT. He serves as a consultant to a number of biotech and pharma companies and sits on the Boards of Directors of Polypore International, Inc., LS9, Inc., Mitra (India), GreenLight Bioscience, Essentient, Inc. and Biocon, Ltd (India) and was previously on the Boards of Genzyme, Cuno, Inc., Pall Corp. and Astra.



CollierEarl M. (Duke) Collier, Jr. is Executive Chairman of Arsenal Medical and serves as CEO of 480 Biomedical. For many years, Mr. Collier was executive vice president at Genzyme Corporation. He has also served as president of Vitas Healthcare and a partner at the law firm of Hogan and Hartson. Mr. Collier sits on the boards of 480 Biomedical, Arsenal Medical, Capricor, Transmedics and Newton-Wellesley Hospital.



ChereauFrederic Chereau serves as president and chief operating officer of aTyr Pharma. Previously, Mr. Chereau was senior vice president of Global Angioedema Franchise Lead at Shire, chief executive officer of Pervasis Therapeutics (acquired by Shire in 2012),  vice president and general manager of the Cardiovascular Business Unit at Genzyme from 1999 to 2008, and he started his career at Hemotech.



More information here.